The Rev. Jeff Hood has made a career of fighting to save men the state wants to kill — and it doesn't matter if they're ...

Oct. 9, 2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor ...

Rutgers Health researchers have discovered that networks of misplaced immune cells drive an aggressive lung disease, ...

Despite the high incidence of brain metastasis after resection of non-small cell lung cancer (NSCLC), the National Comprehensive Cancer Network guidelines do not recommend central nervous system (CNS) ...

Scientists are looking for answers about how these confounding trips, known as metastases, occur throughout the human body ...

B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most ...

Rutgers Health researchers have discovered that networks of misplaced immune cells drive an aggressive lung disease ... a plasma cell cancer, could potentially be repurposed to treat IPF.

Life expectancy for people with metastatic or metastasized lung cancer is low. The 5-year survival rate for small cell lung cancer is 3%, and 8% for non-small cell lung cancer (NSCLC). 25-30% of ...

Doctors stage non-small cell lung cancer (NSCLC) according to how far it has progressed. Stages range from occult (or hidden) cancer to stage 4 cancer, in which multiple organs may be affected.

Alecensa is used to treat non-small-cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive. Some types of lung cancer can be treated with a drug that works when it is combined ...